Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome.
OBJECTIVE
To determine if latanoprost reduces intraocular pressure in eyes with glaucoma associated with Sturge-Weber syndrome.


METHODS
We conducted a prospective study in which eyes with uncontrolled intraocular pressure associated with Sturge-Weber syndrome were treated with latanoprost 0.005% once daily. All eyes were already receiving at least two other antiglaucoma medications. Intraocular pressure was measured at baseline and after treatment for at least 1 month. All intraocular pressure measurements were taken within 24 hours of drug instillation.


RESULTS
Six eyes of six patients received latanoprost. Two (28%) of the six eyes demonstrated an intraocular pressure decrease that averaged 8.8 mm Hg. These two responders had juvenile onset glaucoma, whereas the four nonresponders had congenital onset glaucoma.


CONCLUSIONS
Latanoprost may significantly reduce intraocular pressure in selected patients with glaucoma associated with Sturge-Weber syndrome.
Eye Physician Associates, S.C., Milwaukee, Wisconsin, USA.
C B
CB
Yang
S F
SF
Freedman
J S
JS
Myers
E G
EG
Buckley
L W
LW
Herndon
R R
RR
Allingham
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005901:Glaucoma / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007715:Klippel-Trenaunay-Weber Syndrome / Q000150:complications*; D000077338:Latanoprost; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D013341:Sturge-Weber Syndrome / Q000150:complications*
D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost